Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077018 | 1.00 | BCL2A1 (0.41) | BCL2A1ALDH1A1RAB9AHTTPPARG | |
| SCHEMBL6412482 | 0.90 | BCL2A1 (0.44) | BCL2A1ALDH1A1RAB9AHTT | |
| SCHEMBL6412487 | 0.90 | BCL2A1 (0.44) | BCL2A1ALDH1A1RAB9AHTT | |
| SCHEMBL6876915 | 0.89 | BCL2A1 (0.43) | BCL2A1ALDH1A1RAB9AHTTPPARG | |
| SCHEMBL6876913 | 0.89 | BCL2A1 (0.43) | BCL2A1ALDH1A1RAB9AHTTPPARG | |
| SCHEMBL6077162 | 0.88 | KDM4E (0.42) | ALDH1A1RAB9APKMKDM4E | |
| SCHEMBL6077166 | 0.88 | KDM4E (0.42) | ALDH1A1RAB9APKMKDM4E | |
| SCHEMBL6077249 | 0.86 | CA12 (0.42) | BCL2A1ALDH1A1RAB9AKDM4E | |
| SCHEMBL6076507 | 0.86 | ALDH1A1 (0.45) | BCL2A1ALDH1A1HTT | |
| SCHEMBL6076512 | 0.86 | ALDH1A1 (0.45) | BCL2A1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | BCL2A1 2797/4885ALDH1A1 563/4885RAB9A 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.